Atrial Fibrillation Risk Assessment Pathway v4.0
Stroke vs. Bleeding Synthesis Engine · CHA₂DS₂-VASc & HAS-BLED
📈 Comprehensive Synthesis: Enter the patient’s profile below. The engine will simultaneously calculate the standard or renal-adjusted Stroke risk alongside HAS-BLED, generating a unified, guideline-directed anticoagulation strategy.
1 Core Patient Profile
2 Stroke Risk Factors (CHA₂DS₂-VASc)
3 Bleeding Specific Factors (HAS-BLED)
📚 Clinical Application & Nuances
⚠ The “Female Sex” Misconception
Female sex is a risk modifier, not an independent risk factor. In the absence of other CHA₂DS₂-VASc factors, a biological female scores a 1, but this does NOT confer significant stroke risk and OAC is NOT recommended.
Female sex is a risk modifier, not an independent risk factor. In the absence of other CHA₂DS₂-VASc factors, a biological female scores a 1, but this does NOT confer significant stroke risk and OAC is NOT recommended.
The R₂CHA₂DS₂-VASc Upgrade
Renal impairment is a potent, independent predictor of stroke in AFib. The R₂CHA₂DS₂-VASc score assigns 2 points for a Creatinine Clearance < 60 mL/min. This improves net reclassification, identifying high-risk patients who might otherwise falsely appear as ‘low risk’ on the standard scale.
The HAS-BLED Fallacy
A high HAS-BLED score (≥ 3) should never be used in isolation to deny a patient OAC if their stroke risk is high. It should be used to flag the need for closer monitoring and to actively correct modifiable bleeding risks (e.g., optimising BP, stopping NSAIDs, reducing alcohol intake).
NOACs vs. Warfarin (VKA)A high HAS-BLED score (≥ 3) should never be used in isolation to deny a patient OAC if their stroke risk is high. It should be used to flag the need for closer monitoring and to actively correct modifiable bleeding risks (e.g., optimising BP, stopping NSAIDs, reducing alcohol intake).
- NOACs (Apixaban, Rivaroxaban, Dabigatran): Recommended as first-line therapy over Warfarin in eligible patients with AFib due to a significantly lower risk of intracranial haemorrhage and no need for routine INR monitoring.
- Strict Warfarin Indications: NOACs are absolutely contraindicated in patients with Mechanical Heart Valves and Moderate-to-Severe Mitral Stenosis (Rheumatic AFib). Warfarin is the only approved therapy for these patients.
Abbreviations: OAC (Oral Anticoagulant) · NOAC (Non-Vitamin K Oral Anticoagulant) · VKA (Vitamin K Antagonist) · AFib (Atrial Fibrillation) · CHF (Congestive Heart Failure) · TIA (Transient Ischaemic Attack) · PAD (Peripheral Artery Disease) · CrCl (Creatinine Clearance)
⚠ Clinical Disclaimer: These algorithms are clinical decision aids validated for non-valvular atrial fibrillation. OAC initiation must involve shared decision-making, considering patient values, absolute stroke risk, and absolute bleeding risk.
© 2026 Dr Shashikiran Umakanth · MEDiscuss.org · All rights reserved.
Atrial Fibrillation Risk Assessment Pathway — Clinical decision support for educational purposes. Unauthorised reproduction, redistribution, or modification of this tool is prohibited. For permissions, contact mediscuss.org/contact.
Algorithm References & Evidence Base
- Friberg L, et al. Evaluation of risk stratification schemes for ischaemic stroke and bleeding… Eur Heart J. 2012.
- Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding… Chest. 2010.
- Piccini JP, et al. Renal function and the risk of stroke in patients with atrial fibrillation (R2CHADS2). Circulation. 2013.
- Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021.
MEDiscuss Clinical Decision Support Suite
Access all evidence-based algorithms, prognostic matrices, and pharmacotherapeutic pathways.
← View All Clinical Modules
